ArticleAdvances in therapy2022

Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.

Bijal D Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.